$6.870
-0.475 (-6.91%)Zum Schluss
OCUL-News
OCUL-Events
Ocular Therapeutix Shares Drop 18.2% to $7.89
Ocular Therapeutix is down -18.2%, or -$1.76 to $7.89.
Ocular Therapeutix Shares Drop 22% to $7.53
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degeneration drug candidate, 4D-150. Ocular Therapeutix is also developing a flagship wet AMD treatment, AXPAXLI, and preparing for its own FDA filing in Q4.
Ocular Therapeutix Shares Down 18.1% to $7.90
Ocular Therapeutix is down -18.1%, or -$1.75 to $7.90.
Ocular Therapeutix Completes Axpaxli NDA Pre-Meeting
Ocular Therapeutix announced the completion of its pre-new drug application, or NDA, meeting with the FDA for its investigational product candidate Axpaxli for the treatment of wet age-related macular degeneration. Based on the pre-NDA meeting, the company's expectations for the Axpaxli NDA package remain consistent with prior FDA communications, including the May Type C meeting. Ocular remains on track to submit the NDA in the fourth quarter of 2026.
Ocular Therapeutix Stock Price Rises
Ocular Therapeutix is up…
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.